Volume 19: Issue 2 (Oct 2020): Primary and Secondary Glomerular Diseases

Wei SC , Duffy CR , Allison JP : Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8: 1069–1086, 2018 PubMed

• PubMed
Wei SC , Duffy CR , Allison JP : Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8: 1069–1086, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Larkin J , Chiarion-Sileni V , Gonzalez R , Grob JJ , Cowey CL , Lao CD , et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 375: 23–34, 20158 PubMed

• PubMed
Larkin J , Chiarion-Sileni V , Gonzalez R , Grob JJ , Cowey CL , Lao CD , : Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 375: 23–34, 20158 PubMed )| false
• Search Google Scholar
• Export Citation

Gandhi L , Rodríguez-Abreu D , Gadgeel S , Esteban E , Felip E , De Angelis F , et al.; KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078–2092, 2018 PubMed

• PubMed
Gandhi L , Rodríguez-Abreu D , Gadgeel S , Esteban E , Felip E , De Angelis F , ; KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078–2092, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Motzer RJ , Tannir NM , McDermott DF , Aren Frontera O , Melichar B , Choueiri TK , et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378: 1277–1290, 2018 PubMed

• PubMed
Motzer RJ , Tannir NM , McDermott DF , Aren Frontera O , Melichar B , Choueiri TK , : Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378: 1277–1290, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Postow MA , Callahan MK , Wolchok JD Immune checkpoint blockade in cancer therapy. J Clin Oncol 33: 1974–1982, 2015 PubMed

• PubMed
Postow MA , Callahan MK , Wolchok JD Immune checkpoint blockade in cancer therapy. J Clin Oncol 33: 1974–1982, 2015 PubMed )| false
• Search Google Scholar
• Export Citation

Postow MA , Sidlow R , Hellmann MD : Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158–168, 2018 PubMed

• PubMed
Postow MA , Sidlow R , Hellmann MD : Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158–168, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Perazella MA , Shirali AC Nephrotoxicity of cancer immunotherapies: Past, present and future. J Am Soc Nephrol 29: 2039–2052, 2018 PubMed

• PubMed
Perazella MA , Shirali AC Nephrotoxicity of cancer immunotherapies: Past, present and future. J Am Soc Nephrol 29: 2039–2052, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Cortazar FB , Kibbelaar ZA , Glezerman IG , Abudayyeh A , Mamlouk O , Motwani SS , et al.: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol 31: 435–446, 2020 PubMed

• PubMed
Cortazar FB , Kibbelaar ZA , Glezerman IG , Abudayyeh A , Mamlouk O , Motwani SS , : Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol 31: 435–446, 2020 PubMed )| false
• Search Google Scholar
• Export Citation

Cortazar FB , Marrone KA , Troxell ML , Ralto KM , Hoenig MP , Brahmer JR , et al.: Clinicopathologic features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638–647, 2016 PubMed

• PubMed
Cortazar FB , Marrone KA , Troxell ML , Ralto KM , Hoenig MP , Brahmer JR , : Clinicopathologic features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638–647, 2016 PubMed )| false
• Search Google Scholar
• Export Citation

Horvat TZ , Adel NG , Dang TO , Momtaz P , Postow MA , Callahan MK , et al.: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipulimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33: 3193–3198, 2015 PubMed

• PubMed
Horvat TZ , Adel NG , Dang TO , Momtaz P , Postow MA , Callahan MK , : Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipulimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33: 3193–3198, 2015 PubMed )| false
• Search Google Scholar
• Export Citation

Weber JS , Hodi FS , Wolchok JD , Topalian SL , Schadendorf D , Larkin J , et al.: Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785–792, 2017 PubMed

• PubMed
Weber JS , Hodi FS , Wolchok JD , Topalian SL , Schadendorf D , Larkin J , : Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785–792, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Mamlouk O , Selamet U , Machado S , Abdelrahim M , Glass WF , Tchakarov A , et al.: Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience. J Immunother Cancer 7: 2, 2019 PubMed

• PubMed
Mamlouk O , Selamet U , Machado S , Abdelrahim M , Glass WF , Tchakarov A , : Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience. J Immunother Cancer 7: 2, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Fadel F , El Karoui K , Knebelmann B : Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211–212, 2009 PubMed

• PubMed
Fadel F , El Karoui K , Knebelmann B : Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211–212, 2009 PubMed )| false
• Search Google Scholar
• Export Citation

Kishi S , Minato M , Saijo A , Murakami N , Tamaki M , Matsuura M , et al.: IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 57 1257–1263, 2018 PubMed

• PubMed
Kishi S , Minato M , Saijo A , Murakami N , Tamaki M , Matsuura M , : IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 57 1257–1263, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Jung K , Zeng X , Bilusic M Nivolumab-associated acute glomerulonephritis: A case report and literature review. BMC Nephrol 17: 188, 2016 PubMed

• PubMed
Jung K , Zeng X , Bilusic M Nivolumab-associated acute glomerulonephritis: A case report and literature review. BMC Nephrol 17: 188, 2016 PubMed )| false
• Search Google Scholar
• Export Citation

van den Brom RR , Abdulahad WH , Rutgers A , Kroesen BJ , Roozendaal C , de Groot DJ , et al.: Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 55: 1143–1145, 2016 PubMed

• PubMed
van den Brom RR , Abdulahad WH , Rutgers A , Kroesen BJ , Roozendaal C , de Groot DJ , : Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 55: 1143–1145, 2016 PubMed )| false
• Search Google Scholar
• Export Citation

Kitchlu A , Fingrut W , Avila-Casado C , Chan CT , Crump M , Hogg D , et al.: Nephrotic syndrome with cancer immunotherapies: A report of 2 cases. Am J Kidney Dis 70: 581–585, 2017 PubMed

• PubMed
Kitchlu A , Fingrut W , Avila-Casado C , Chan CT , Crump M , Hogg D , : Nephrotic syndrome with cancer immunotherapies: A report of 2 cases. Am J Kidney Dis 70: 581–585, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Daanen RA , Maas RJH , Koornstra RHT , Steenbergen EJ , van Herpen CML , Willemsen AECAB : Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report. J Immunother 40: 345–348, 2017 PubMed

• PubMed
Daanen RA , Maas RJH , Koornstra RHT , Steenbergen EJ , van Herpen CML , Willemsen AECAB : Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report. J Immunother 40: 345–348, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Estrada CC , Maldonado A , Mallipattu SK Therapeutic inhibition of VEGF signaling and associated nephrotoxicities, J Am Soc Nephrol 30: 187–200, 2019 PubMed

• PubMed
Estrada CC , Maldonado A , Mallipattu SK Therapeutic inhibition of VEGF signaling and associated nephrotoxicities, J Am Soc Nephrol 30: 187–200, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Arnold D , Fuchs CS , Tabernero J , Ohtsu A , Zhu AX , Garon EB , et al.: Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramjcirumab.Ann Oncol 28: 2932–2942, 2017 PubMed

• PubMed
Arnold D , Fuchs CS , Tabernero J , Ohtsu A , Zhu AX , Garon EB , : Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramjcirumab. Ann Oncol 28: 2932–2942, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Izzedine H , Escudier B , Lhomme C , Pautier P , Rouvier P , Gueutin V , et al.: Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): An 8-year observational study at a single center. Medicine (Baltimore) 93: 333–339, 2014 PubMed

• PubMed
Izzedine H , Escudier B , Lhomme C , Pautier P , Rouvier P , Gueutin V , : Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): An 8-year observational study at a single center. Medicine (Baltimore) 93: 333–339, 2014 PubMed )| false
• Search Google Scholar
• Export Citation

Burton GJ , Redman CW , Roberts JM , Moffett A : Pre-eclampsia: pathophysiology and clinical implications. BMJ 366: l2381, 2019 PubMed

• PubMed
Burton GJ , Redman CW , Roberts JM , Moffett A : Pre-eclampsia: pathophysiology and clinical implications. BMJ 366: l2381, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Nobakht N , Nguyen HA , Kamgar MK , Abdelnour L , Rastogi A , Hanna RM Development of collapsing focal and segmental glomerulosclerosis after receiving vascular endothelial growth factor blockade. Kidney Int Rep 4: 1508–1512, 2019 PubMed

• PubMed
Nobakht N , Nguyen HA , Kamgar MK , Abdelnour L , Rastogi A , Hanna RM Development of collapsing focal and segmental glomerulosclerosis after receiving vascular endothelial growth factor blockade. Kidney Int Rep 4: 1508–1512, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Nihei S , Sato J , Harada T , Kuyama S , Suzuki T , Waga N , et al.: Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother Pharmacol 81: 1051–1059, 2018 PubMed

• PubMed
Nihei S , Sato J , Harada T , Kuyama S , Suzuki T , Waga N , : Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother Pharmacol 81: 1051–1059, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Hanna RM , Barsoum M , Arman F , Selamet U , Hasnain H , Kurtz I : Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: Emerging evidence.Kidney Int 96: 572–580, 2019 PubMed

• PubMed
Hanna RM , Barsoum M , Arman F , Selamet U , Hasnain H , Kurtz I : Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: Emerging evidence. Kidney Int 96: 572–580, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Avery RL , Castellarin AA , Steinle NC , Dhoot DS , Pieramici DJ , See R , et al.: Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizjmab. Retina 37: 1847–1858 2017 PubMed

• PubMed
Avery RL , Castellarin AA , Steinle NC , Dhoot DS , Pieramici DJ , See R , : Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizjmab. Retina 37: 1847–1858 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Hanna RM , Lopez EA , Hasnain H , Selamet U , Wilson J , Youssef PN , et al.: Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J 12: 92–100, 2019 PubMed

• PubMed
Hanna RM , Lopez EA , Hasnain H , Selamet U , Wilson J , Youssef PN , : Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J 12: 92–100, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Touzani F , Geers C , Pozdzik A Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol 2019: 2919080, 2019 PubMed

• PubMed
Touzani F , Geers C , Pozdzik A Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol 2019: 2919080, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Glassman AR , Liu D , Jampol LM , Sun JK , Diabetic Retinopathy Clinical Research Network: Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci 59: 1199–1205, 2018 PubMed

• PubMed
Glassman AR , Liu D , Jampol LM , Sun JK , Diabetic Retinopathy Clinical Research Network: Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci 59: 1199–1205, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Qin S , Li A , Yi M , Yu S , Zhang M , Wu K Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 12: 27, 2019 PubMed

• PubMed
Qin S , Li A , Yi M , Yu S , Zhang M , Wu K Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 12: 27, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Liu B , Ding F , Liu Y , Xiong G , Lin T , He D , et al.: Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 17: 67661–67673, 2016 PubMed

• PubMed
Liu B , Ding F , Liu Y , Xiong G , Lin T , He D , : Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 17: 67661–67673, 2016 PubMed )| false
• Search Google Scholar
• Export Citation

Zhang ZF , Wang T , Liu LH , Guo HQ Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. PLoS One 9: e90135, 2014 PubMed

• PubMed
Zhang ZF , Wang T , Liu LH , Guo HQ Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. PLoS One 9: e90135, 2014 PubMed )| false
• Search Google Scholar
• Export Citation

Izzedine H , Mangier M , Ory V , Zhang SY , Sendeyo K , Bouachi K , et al.: Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85: 457–470, 2014 PubMed

• PubMed
Izzedine H , Mangier M , Ory V , Zhang SY , Sendeyo K , Bouachi K , : Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85: 457–470, 2014 PubMed )| false
• Search Google Scholar
• Export Citation

Arrestier R , Satie AP , Zhang SY , Plaisier E , Isnard-Bagnis C , Gatault P , et al.: Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: A retrospective study of 8 cases. BMC Nephrol 19: 331, 2018 PubMed

• PubMed
Arrestier R , Satie AP , Zhang SY , Plaisier E , Isnard-Bagnis C , Gatault P , : Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: A retrospective study of 8 cases. BMC Nephrol 19: 331, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Brodsky S , Eikelboom J , Hebert LA Anticoagulant-related nephropathy. J Am Soc Nephrol 29: 2787–2793 2009 PubMed

• PubMed
Brodsky S , Eikelboom J , Hebert LA Anticoagulant-related nephropathy. J Am Soc Nephrol 29: 2787–2793 2009 PubMed )| false
• Search Google Scholar
• Export Citation

Golbin L , Vigneau C , Touchard G , Thervet E , Halimi JM , Sawadogo T , et al.: Warfarin-related nephropathy induced by three different vitamin K antagonists: Analysis of 13 biopsy-proven cases. Clin Kidney J 10: 381–388, 2017 PubMed

• PubMed
Golbin L , Vigneau C , Touchard G , Thervet E , Halimi JM , Sawadogo T , : Warfarin-related nephropathy induced by three different vitamin K antagonists: Analysis of 13 biopsy-proven cases. Clin Kidney J 10: 381–388, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Brodsky SV , Satoskar A , Chen J , Nadasdy G , Eagen JW , Hamirani M , et al.: Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: A report of 9 cases. Am J Kidney Dis 54: 1121–1126, 2009 PubMed

• PubMed
Brodsky SV , Satoskar A , Chen J , Nadasdy G , Eagen JW , Hamirani M , : Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: A report of 9 cases. Am J Kidney Dis 54: 1121–1126, 2009 PubMed )| false
• Search Google Scholar
• Export Citation

Awesat J , Sagy I , Haviv YS , Rabinovich A , Jotkowitz A , Shleyfer E , et al.: Dabigatran-induced nephropathy and its successful treatment with idarucizumab: Case report and literature review. Thromb Res 169: 120–122, 2018 PubMed

• PubMed
Awesat J , Sagy I , Haviv YS , Rabinovich A , Jotkowitz A , Shleyfer E , : Dabigatran-induced nephropathy and its successful treatment with idarucizumab: Case report and literature review. Thromb Res 169: 120–122, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Brodsky SV , Mhaskar NS , Thiruveedi S , Dhingra R , Reuben SC , Calomeni E , et al.: Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related therapy. Kidney Res Clin Pract 36: 387–392, 2017 PubMed

• PubMed
Brodsky SV , Mhaskar NS , Thiruveedi S , Dhingra R , Reuben SC , Calomeni E , : Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related therapy. Kidney Res Clin Pract 36: 387–392, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Yao X , Tangri N , Gersh BJ , Sangaralingham LR , Shah ND , Nath KA , et al.: Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 70: 2621–2632, 2017 PubMed

• PubMed
Yao X , Tangri N , Gersh BJ , Sangaralingham LR , Shah ND , Nath KA , : Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 70: 2621–2632, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Shin JI , Luo S , Alexander GC , Inker LA , Coresh J , Chang AR , et al.: Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. J Am Coll Cardiol 71: 251–252, 2018 PubMed

• PubMed
Shin JI , Luo S , Alexander GC , Inker LA , Coresh J , Chang AR , : Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. J Am Coll Cardiol 71: 251–252, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Shroff GR , Stoecker R , Hart A : Non-vitamin K-dependent oral anticoagulants for nonvalvular atrial fibrillation in patients with CKD: Pragmatic considerations for the clinician. Am J Kidney Dis 72: 717–727, 2018 PubMed

• PubMed
Shroff GR , Stoecker R , Hart A : Non-vitamin K-dependent oral anticoagulants for nonvalvular atrial fibrillation in patients with CKD: Pragmatic considerations for the clinician. Am J Kidney Dis 72: 717–727, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Pollack CV Jr , Reilly PA , van Ryn J , Eikelboom JW , Glund S , Bernstein RA , et al.: Idarucizumab for dabigatran reversal: Full cohort analysis. N Engl J Med 377: 431–441, 2017 PubMed

• PubMed
Pollack CV Jr , Reilly PA , van Ryn J , Eikelboom JW , Glund S , Bernstein RA , : Idarucizumab for dabigatran reversal: Full cohort analysis. N Engl J Med 377: 431–441, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Connolly SJ , Crowther M , Eikelboom JW , Gibson CM , Curnutte JT , Lawrence JH , et al.: Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380: 1326–1335, 2019 PubMed

• PubMed
Connolly SJ , Crowther M , Eikelboom JW , Gibson CM , Curnutte JT , Lawrence JH , : Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380: 1326–1335, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Lühe A , Künkele K-P , Haiker M , Schad K , Zihlmann C , Bauss F , et al.: Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety. Toxicol In Vitro 22: 899–909, 2008 PubMed

• PubMed
Lühe A , Künkele K-P , Haiker M , Schad K , Zihlmann C , Bauss F , : Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety. Toxicol In Vitro 22: 899–909, 2008 PubMed )| false
• Search Google Scholar
• Export Citation

Hiroi-Furuya E , Kameda T , Hiura K , Mano H , Miyazawa K , Nakamaru Y , et al.: Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 64: 219–223, 1999 PubMed

• PubMed
Hiroi-Furuya E , Kameda T , Hiura K , Mano H , Miyazawa K , Nakamaru Y , : Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 64: 219–223, 1999 PubMed )| false
• Search Google Scholar
• Export Citation

Sauter M , Jülg B , Porubsky S , Cohen C , Fischereder M , Sitter T , et al.: Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47: 1075–1080, 2006 PubMed

• PubMed
Sauter M , Jülg B , Porubsky S , Cohen C , Fischereder M , Sitter T , : Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47: 1075–1080, 2006 PubMed )| false
• Search Google Scholar
• Export Citation

Markowitz GS , Appel GB , Fine PL , Fenves AZ , Loon NR , Jagannath S , et al.: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164–1172, 2001 PubMed

• PubMed
Markowitz GS , Appel GB , Fine PL , Fenves AZ , Loon NR , Jagannath S , : Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164–1172, 2001 PubMed )| false
• Search Google Scholar
• Export Citation

Barri YM , Munshi NC , Sukumalchantra S , Abulezz SR , Bonsib SM , Wallach J , et al.: Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65: 634–641, 2004 PubMed

• PubMed
Barri YM , Munshi NC , Sukumalchantra S , Abulezz SR , Bonsib SM , Wallach J , : Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65: 634–641, 2004 PubMed )| false
• Search Google Scholar
• Export Citation

Desikan R , Veksler Y , Raza S , Stokes B , Sabir T , Li ZJ , et al.: Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119: 496–499, 2002 PubMed

• PubMed
Desikan R , Veksler Y , Raza S , Stokes B , Sabir T , Li ZJ , : Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119: 496–499, 2002 PubMed )| false
• Search Google Scholar
• Export Citation

Shreedhara M , Fenves AZ , Benavides D , Stone MJ : Reversibility of pamidronate-associated glomerulosclerosis. Proc Bayl Univ Med Cent 20: 249–253, 2007 PubMed

• PubMed
Shreedhara M , Fenves AZ , Benavides D , Stone MJ : Reversibility of pamidronate-associated glomerulosclerosis. Proc Bayl Univ Med Cent 20: 249–253, 2007 PubMed )| false
• Search Google Scholar
• Export Citation

Banerjee D , Asif A , Striker L , Preston RA , Bourgoignie JJ , Roth D Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41: E18, 2006 PubMed

• PubMed
Banerjee D , Asif A , Striker L , Preston RA , Bourgoignie JJ , Roth D Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41: E18, 2006 PubMed )| false
• Search Google Scholar
• Export Citation

Smetana S , Michlin A , Rosenman E , Biro A , Boaz M , Katzir Z : Pamidronate-induced nephrotoxic tubular necrosis: A case report. Clin Nephrol 61: 63–67, 2004 PubMed

• PubMed
Smetana S , Michlin A , Rosenman E , Biro A , Boaz M , Katzir Z : Pamidronate-induced nephrotoxic tubular necrosis: A case report. Clin Nephrol 61: 63–67, 2004 PubMed )| false
• Search Google Scholar
• Export Citation

Buysschaert M , Cosyns JP , Barreto L , Jadoul M : Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18: 826–829, 2003 PubMed

• PubMed
Buysschaert M , Cosyns JP , Barreto L , Jadoul M : Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18: 826–829, 2003 PubMed )| false
• Search Google Scholar
• Export Citation

Markowitz GS , Fine PL , Stack JI , Kunis CL , Radhakrishnan J , Palecki W , et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281–289, 2003 PubMed

• PubMed
Markowitz GS , Fine PL , Stack JI , Kunis CL , Radhakrishnan J , Palecki W , : Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281–289, 2003 PubMed )| false
• Search Google Scholar
• Export Citation

Bodmer M , Amico P , Mihatsch MJ , Haschke M , Kummer O , Krähenbühl S , et al.: Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 22: 2366–2370, 2007 PubMed

• PubMed
Bodmer M , Amico P , Mihatsch MJ , Haschke M , Kummer O , Krähenbühl S , : Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 22: 2366–2370, 2007 PubMed )| false
• Search Google Scholar
• Export Citation

Avguštin N , Kovač D , Kojc N , Mlinšek G , Lindič J : Acute granulomatous interstitial nephritis and acute rejection in a kidney transplant recipient after zoledronic acid therapy: A case report and review of the literature. Clin Nephrol 88: 97–100, 2017 PubMed

• PubMed
Avguštin N , Kovač D , Kojc N , Mlinšek G , Lindič J : Acute granulomatous interstitial nephritis and acute rejection in a kidney transplant recipient after zoledronic acid therapy: A case report and review of the literature. Clin Nephrol 88: 97–100, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Anderson K , Ismaila N , Flynn PJ , Halabi S , Jaganna S , Ogaily MS , et al.: Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 36: 812–818, 2018 PubMed

• PubMed
Anderson K , Ismaila N , Flynn PJ , Halabi S , Jaganna S , Ogaily MS , : Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 36: 812–818, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Berenson JR , Lichtenstein A , Porter L , Dimopoulos MA , Bordoni R , George S , et al.; Myeloma Aredia Study Group: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488–493, 1996 PubMed

• PubMed
Berenson JR , Lichtenstein A , Porter L , Dimopoulos MA , Bordoni R , George S , ; Myeloma Aredia Study Group: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488–493, 1996 PubMed )| false
• Search Google Scholar
• Export Citation

Lipton A , Theriault RL , Hortobagyi GN , Simeone J , Knight RD , Mellars K , et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082–1090, 2000 PubMed

• PubMed
Lipton A , Theriault RL , Hortobagyi GN , Simeone J , Knight RD , Mellars K , : Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082–1090, 2000 PubMed )| false
• Search Google Scholar
• Export Citation

Chang JT , Green L , Beitz J : Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676–1679, discussion 1676–1679, 2003 PubMed

• PubMed
Chang JT , Green L , Beitz J : Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676–1679, discussion 1676–1679, 2003 PubMed )| false
• Search Google Scholar
• Export Citation

McDermott RS , Kloth DD , Wang H , Hudes GR , Langer CJ : Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 4: 524–529, 2006 PubMed

• PubMed
McDermott RS , Kloth DD , Wang H , Hudes GR , Langer CJ : Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 4: 524–529, 2006 PubMed )| false
• Search Google Scholar
• Export Citation

Wilson LM , Rebholz CM , Jirru E , Liu MC , Zhang A , Gayleard J , et al.: Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 166: 649–658, 2017 PubMed

• PubMed
Wilson LM , Rebholz CM , Jirru E , Liu MC , Zhang A , Gayleard J , : Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 166: 649–658, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Cipriani C , Pepe J , Clementelli C , Manai R , Colangelo L , Fassino V , et al.: Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: A pilot study. Br J Clin Pharmacol 83: 2266–2273, 2017 PubMed

• PubMed
Cipriani C , Pepe J , Clementelli C , Manai R , Colangelo L , Fassino V , : Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: A pilot study. Br J Clin Pharmacol 83: 2266–2273, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Im H , Choi HM , Oh D-J , Kwon YE : Severe acute kidney injury after single-dose injection of zoledronic acid in an elderly patient. Am J Ther 25: e289–e290, 2018 PubMed

• PubMed
Im H , Choi HM , Oh D-J , Kwon YE : Severe acute kidney injury after single-dose injection of zoledronic acid in an elderly patient. Am J Ther 25: e289–e290, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Perazella MA , Markowitz GS : Bisphosphonate nephrotoxicity. Kidney Int 74: 1385–1393, 2008 PubMed

• PubMed
Perazella MA , Markowitz GS : Bisphosphonate nephrotoxicity. Kidney Int 74: 1385–1393, 2008 PubMed )| false
• Search Google Scholar
• Export Citation

Raje N , Terpos E , Willenbacher W , Shimizu K , García-Sanz R , Durie B , et al.: Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19: 370–381, 2018 PubMed

• PubMed
Raje N , Terpos E , Willenbacher W , Shimizu K , García-Sanz R , Durie B , : Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19: 370–381, 2018 PubMed )| false
• Search Google Scholar
• Export Citation

Markowitz GS , Bomback AS , Perazella MA : Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 10: 1291–1299, 2015 PubMed

• PubMed
Markowitz GS , Bomback AS , Perazella MA : Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 10: 1291–1299, 2015 PubMed )| false
• Search Google Scholar
• Export Citation

Mérida E , Praga M : NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol 14: 1280–1282, 2019 PubMed

• PubMed
Mérida E , Praga M : NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol 14: 1280–1282, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Radford MG Jr , Holley KE , Grande JP , Larson TS , Wagoner RD , Donadio JV , et al.: Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 276: 466–469, 1996 PubMed

• PubMed
Radford MG Jr , Holley KE , Grande JP , Larson TS , Wagoner RD , Donadio JV , : Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 276: 466–469, 1996 PubMed )| false
• Search Google Scholar
• Export Citation

Beck LH Jr : PLA2R and THSD7A: Disparate paths to the same disease? J Am Soc Nephrol 28: 2579–2589, 2017 PubMed

• PubMed
Beck LH Jr : PLA2R and THSD7A: Disparate paths to the same disease? J Am Soc Nephrol 28: 2579–2589, 2017 PubMed )| false
• Search Google Scholar
• Export Citation

Sethi S , Debiec H , Madden B , Charlesworth MC , Morelle J , Gross L , et al.: Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 97: 163–174, 2020 PubMed

• PubMed
Sethi S , Debiec H , Madden B , Charlesworth MC , Morelle J , Gross L , : Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 97: 163–174, 2020 PubMed )| false
• Search Google Scholar
• Export Citation

Bakhriansyah M , Souverein PC , van den Hoogen MWF , de Boer A , Klungel OH : Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users. Clin J Am Soc Nephrol 14: 1355–1362, 2019 PubMed

• PubMed
Bakhriansyah M , Souverein PC , van den Hoogen MWF , de Boer A , Klungel OH : Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users. Clin J Am Soc Nephrol 14: 1355–1362, 2019 PubMed )| false
• Search Google Scholar
• Export Citation

Pendergraft WF 3rd , Niles JL : Trojan horses: Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 26: 42–49, 2014 PubMed

• PubMed
Pendergraft WF 3rd , Niles JL : Trojan horses: Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 26: 42–49, 2014 PubMed )| false
• Search Google Scholar
• Export Citation

McGrath MM , Isakova T , Rennke HG , Mottola AM , Laliberte KA , Niles JL : Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 6: 2799–2805, 2011 PubMed

• PubMed
McGrath MM , Isakova T , Rennke HG , Mottola AM , Laliberte KA , Niles JL : Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 6: 2799–2805, 2011 PubMed )| false
• Search Google Scholar
• Export Citation